Effective case-finding of osteoporosis in a Fracture and Osteoporosis Clinic in Groningen: An analysis of the first 100 patients

Aktuelle Traumatologie

Volumn 35, Issue 1, 2005, Pages 34-39

  Hegeman, J H ^a,b,d   Willemsen, G ^a,c   Van Nieuwpoort, J ^a   Kreeftenberg, H G ^a   Van Der Veer, E ^a   Slaets, J P J ^a   Ten Duis, H J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TWENTEBORG HOSPITAL   (Netherlands)

^c Diaconessen Hospital   (Netherlands)

^d NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACCIDENT; ADULT; ARTICLE; BONE DENSITY; CASE FINDING; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OSTEOPOROSIS; PRACTICE GUIDELINE;

EID: 14844333145     PISSN: 00446173     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-837557     Document Type: Article

References (28)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-1541
2. Burger H, van Daele PLA, Grashuis K, Hofman A, Grobbee DE, Schutte HE, et al. Vertebral deformities and functional impairment in men and women. J Bone Miner Res 1997; 12: 152-157
3. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341: 72-75
4. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture intervention trial. JAMA 1998; 280: 2077-2082
5. Dhesi JK, Moniz C, Close JCT, Jackson SHD, Allain TJ. A rationale for vitamin D prescribing in a falls clinic population. Age Ageing 2002; 31: 267-271
6. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051-1056
7. Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture intervention trial. Arch Intern Med 1997; 157: 2617-2624
8. Fisher A, Davis M. Is there rationale for vitamin D prescribing in the elderly population? Age Ageing 2003; 32: 235-236
9. Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 2000; 82-A: 1063-1070
10. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137-1148
11. Ho YV, Frauman AG, Thomson W, Seeman E. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 2000; 11: 98-101
12. Ismail AA, Cockerill W, Cooper C, Finn JD, Abendroth K, Parisi G, et al. Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European prospective osteoporosis study. Osteoporosis Int 2001; 12: 85-90
13. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporosis Int 1994; 4; 368-381
14. Laet CEDH de, van Hout BA, Pols HA. Osteoporosis in the Netherlands; A burden of illness study. Rotterdam: Institute for Medical Technology Assessment; 1996
15. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Eng J Med 1995; 333: 1437-1443
16. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone density predict occurence of osteoporotic fractures. BMJ 1996; 312: 1254-1259
17. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al. Effect of risedronate on the risk of hip fracture in elderly women. N Eng J Med 2001; 344: 333-340
18. McLellan AR, Gallacher SJ, Fraser M, McQuillan C. The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporosis Int 2003; 14: 1028-1034
19. Melton 3rd LJ, Crowson CS, O'Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporosis Int 1999; 9: 29-37
20. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K et al. The association of radiographically detected vertebral fractures with backpain and function: a prospective study. Ann Intern Med 1998; 128: 793-800
21. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J et al. Alendronate for the treatment of osteoporosis in men. N Eng J Med 2000; 343: 604-610
22. Osteoporose. Tweede herziene richtlijn. Alphen aan den Rijn: Van Zuiden Communications, 2002.
23. Panneman MJM, Lips P, Shuvayu SS, Herings RMC. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 2004; 15: 120-124
24. Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrier-Barriendos J, Gaines K et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVlSTA Comparison Trial) International. J Intern Med 2004: 225: 503-511
25. Schuit SCE, van der Klift M, Weel AEAM, de Laet CEDH, Burger H, Seeman E et al. Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study. Bone 2004; 34: 195-202
26. Seeman E, Eisman JA. Treatment of osteoporosis: why, whom, when and how to treat. Med J Aust 2004; 180: 298-303
27. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the multiple outcomes of raloxifene evaluation study. Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001; 44: 2611-2619
28. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129